Semaglutide in CKD - The Flow Trial NEJM 2024 (Journal Club Idol)

[@mohamedhemida23]

Great work More journal club for nephrology

[@zainabwajih]

Yes yes yes more of this please!!!! Love love love. I agree; I would also like to know if this is just a weightloss effect or GLP1 agonism effect. It would make sense that weightloss would reduce glomerular hyperfiltration. But getting patients to lose weight is not easy so ofcourse this is a huge win. How amazing it is to be a nephro in an era where we have so many drugs that work!

[@kristeenbarker]

Zaina!!!! Couldn’t agree more about weight loss being tricky for patients and absolutely living so many nephrology drugs - the guidelines get outdated quickly. Exciting times. Ps I would absolutely love to see your version of journal club idol! :) x

[@kifacorea]

Nice animations 😊

[@ahmednabil616]

Fantastic as usual

[@kristeenbarker]

Ahmed…you remain one of my favourite humans!

[@ahmednabil616]

@kristeenbarker Thanks, you as well

[@lupinotto5978]

have they done a subgroup analysis of people who where not overweight to see if they still maintained benefit ?

[@kristeenbarker]

Such a great question. I don’t think they did that analysis in the paper at least but could be more subgroup analyses to come.

[@sadiqbaffa8481]

Great. Yes for me.

[@kristeenbarker]

Yay!

[@manamotevaslian3779]

Yes

[@abhishekmj91]

Is it just semaglutide or is it a class effect, tirezepatide leads to more weight loss 15% vs 12%, can we substitute mounjaro for ozempic. Also the other question comes in regards to the funding. I strongly doubt Medicare is gonna pay for a weight loss drug in a non T2DM setting (seeing they refused to publicly fund wegovy/zepbound)

[@kristeenbarker]

Oooo not sure I’m only aware of this phase 3 trial in semeglutide specifically but please let me know if u come across others :)